trending Market Intelligence /marketintelligence/en/news-insights/trending/5sVJEbxpukU3Y3y7s6pa6g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca-Merck's Lynparza gets US FDA priority review in prostate cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca-Merck's Lynparza gets US FDA priority review in prostate cancer

AstraZeneca PLC and Merck & Co. Inc.'s Lynparza was granted priority review in the U.S. to treat patients with a certain type of prostate cancer.

The U.S. Food and Drug Administration is expected to make a decision on the companies' medicine in the second quarter of 2020.

The companies filed a supplemental new drug application for Lynparza, or olaparib, to treat patients with castration-resistant prostate cancer who did not improve following treatment with a new hormonal agent.

The regulator's decision is based on a phase 3 trial called PROfound which found Lynparza was better than Johnson & Johnson's Zytiga, or abiraterone, and Astellas Pharma Inc. and Pfizer Inc.'s Xtandi, or enzalutamide, in treating prostate cancer patients with mutations in their BRCA1/2 or ATM genes.

Lynparza belongs to a class of medicines known as PARP inhibitors, which work by preventing the PARP protein in cancer cells from repairing their damaged DNA — causing them to die instead.

U.K's AstraZeneca and Kenilworth, N.J.-based Merck are developing Lynparza under an $8.5 billion collaboration agreement signed in 2017.

The drug is already approved as a maintenance therapy for certain ovarian cancer patients in the EU, U.S. and Japan. In the U.S., Lynparza is also approved to treat patients with BRCA-mutated breast cancer.